Skip to main content
SpringerLink
Log in

Venous Thromboembolism

  • Chapter
  • First Online:
Book cover Cardiovascular Complications in Cancer Therapy

Part of the book series: Current Clinical Pathology ((CCPATH))

  • 711 Accesses

Abstract

Venous thromboembolism (VTE) is particularly common in cancer patients. Among all patients with VTE, 20% have underlying active malignancy. VTE may be the presenting sign of an occult malignancy, and 10% of patients with idiopathic VTE develop cancer within 2 years. Among hospitalized cancer patients, the cumulative incidence of deep venous thrombosis (DVT) has been reported at 4.6%. On the other hand, up to 50% of cancer patients were found to have evidence of DVT at autopsy. Compared to controls, patients with cancer have a higher risk of first and recurrent VTE, as well as bleeding on anticoagulants.

Currently, the gold standard of VTE treatment is low-molecular-weight heparin, but the results of ongoing trials and a better understanding of bleeding risks related to the pharmacodynamic interaction between direct acting anticoagulants with chemotherapy and better evidence of clinical safety could lead to a change in the therapeutic approach to this pathology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Imberti D, Agnelli G, Ageno W, Moia M, Palareti G, Pistelli R, MASTER Investigators, et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica. 2008;93:273–8. https://doi.org/10.3324/haematol.11458.

    Article  PubMed  Google Scholar 

  2. Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer. 2004;91:92–5. https://doi.org/10.1038/sj.bjc.6601964.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339–46. https://doi.org/10.1002/cncr.23062.

    Article  PubMed  Google Scholar 

  4. Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol). 1999;11:105–10. https://doi.org/10.1053/clon.1999.9023.

    Article  CAS  Google Scholar 

  5. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801. https://doi.org/10.1093/eurheartj/ehw211.

    Article  PubMed  Google Scholar 

  6. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–4. https://doi.org/10.1111/j.1538-7836.2007.02374.x.

    Article  CAS  PubMed  Google Scholar 

  7. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50. https://doi.org/10.1056/NEJM200012213432504.

    Article  CAS  PubMed  Google Scholar 

  8. Kwaan H, Parmar S, Wang J. Pathogenesis of increased risk of thrombosis and cancer. Semin Thromb Hemost. 2003;29:283–90. https://doi.org/10.1055/s-2003-40966.

    Article  CAS  PubMed  Google Scholar 

  9. Lee AY, Levine M. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost. 1999;25:137–45. https://doi.org/10.1055/s-2007-994915.

    Article  CAS  PubMed  Google Scholar 

  10. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4(6):465–73. https://doi.org/10.1038/sj.neo.7900263.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25:173–82. https://doi.org/10.1055/s-2007-994919.

    Article  CAS  PubMed  Google Scholar 

  12. Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol. 1992;81:480–8. https://doi.org/10.1111/j.1365-2141.1992.tb02978.x.

    Article  CAS  PubMed  Google Scholar 

  13. Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in the woman. Arch Intern Med. 1996;156:1806–10. https://doi.org/10.1001/archinte.1996.00440150056006.

    Article  CAS  PubMed  Google Scholar 

  14. Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, et al. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection):e19–26. https://doi.org/10.2459/JCM.0000000000000377.

    Article  CAS  Google Scholar 

  15. Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, et al. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection):e93–e104. https://doi.org/10.2459/JCM.0000000000000383.

    Article  CAS  Google Scholar 

  16. Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17:297–303. https://doi.org/10.1093/annonc/mdj068.

    Article  PubMed  Google Scholar 

  17. Tocchetti CG, Gallucci G, Coppola C, Piscopo G, Cipresso C, Maurea C, et al. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail. 2013;15:482–9. https://doi.org/10.1093/eurjhf/hft008.

    Article  CAS  PubMed  Google Scholar 

  18. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–52. https://doi.org/10.1016/j.chest.2015.11.026.

    Article  PubMed  Google Scholar 

  19. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189–204. https://doi.org/10.1200/JCO.2013.49.1118.

    Article  CAS  PubMed  Google Scholar 

  20. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7. https://doi.org/10.1182/blood-2007-10-116327.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41:81–91. https://doi.org/10.1007/s11239-015-1313-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Escalante CP, Zalpour A, Song J, Richardson MN, Lam T, Halm J, et al. Practice patterns and outcomes of rivaroxaban usage in patients with cancer. J Clin Oncol. 2016;34(26):194. https://doi.org/10.1200/jco.2016.34.26_suppl.194.

    Article  Google Scholar 

  23. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–53. https://doi.org/10.1056/NEJMoa025313.

    Article  CAS  PubMed  Google Scholar 

  24. van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009;01:762. https://doi.org/10.1160/TH08-09-0563.

    Article  CAS  Google Scholar 

  25. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical practice guideline update 2014. J Clin Oncol. 2015;33:654–6. https://doi.org/10.1200/JCO.2014.59.7351.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015;147:475–83. https://doi.org/10.1378/chest.14-0402.

    Article  PubMed  Google Scholar 

  27. Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1:e37–46. https://doi.org/10.1016/S2352-3026(14)70018-3.

    Article  PubMed  Google Scholar 

  28. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72. https://doi.org/10.1161/CIRCULATIONAHA.113.004450.

    Article  CAS  PubMed  Google Scholar 

  29. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338:372–80. https://doi.org/10.1124/jpet.111.180240.

    Article  CAS  PubMed  Google Scholar 

  30. Harvey D, Morgan E. Cancer, inflammation, and therapy: effects on cytochrome p450–mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014;96:449–57. https://doi.org/10.1038/clpt.2014.143.

    Article  CAS  PubMed  Google Scholar 

  31. Trials: NCT 02048865, NCT 02073682, NCT 01708850, and NCT 01727427. [Online] Available at: https://www.clinicaltrials.gov/.

  32. Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314:677–86. https://doi.org/10.1001/jama.2015.9243.

    Article  CAS  PubMed  Google Scholar 

  33. Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM. Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007;22:997–1002. https://doi.org/10.1007/s11606-007-0228-y.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. https://doi.org/10.1186/1477-9560-11-21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114:150–7. https://doi.org/10.1160/TH14-11-0977.

    Article  PubMed  Google Scholar 

  36. Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187–91. https://doi.org/10.1111/jth.13153.

    Article  CAS  PubMed  Google Scholar 

  37. van der Hulle T, den Exter PL, Kooiman J, van der Hoeven JJ, Huisman MV, Klok FA. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost. 2014;12:1116–20. https://doi.org/10.1111/jth.12605.

    Article  CAS  PubMed  Google Scholar 

  38. Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015;136:582–9. https://doi.org/10.1016/j.thromres.2015.07.011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of Hokusai-venous thromboembolism study – methodological implications for clinical trials. J Thromb Haemost. 2013;11:1287–94. https://doi.org/10.1111/jth.12230.

    Article  CAS  PubMed  Google Scholar 

  40. Raskob GE, Van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016;3:e379–87. https://doi.org/10.1016/S2352-3026(16)30057-6.

    Article  PubMed  Google Scholar 

  41. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–24. https://doi.org/10.1056/NEJMoa1711948.

    Article  CAS  PubMed  Google Scholar 

  42. Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist. 2014;19:82–93. https://doi.org/10.1634/theoncologist.2013-0239.

    Article  CAS  PubMed  Google Scholar 

  43. Schulman S, Shrum J, Majeed A. Management of bleeding complications in patients with cancer on DOACs. Thromb Res. 2016;140(Suppl 1):S142–7. https://doi.org/10.1016/S0049-3848(16)30113-X.

    Article  CAS  PubMed  Google Scholar 

  44. Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122:2310–7. https://doi.org/10.1182/blood-2013-04-460162.

    Article  CAS  PubMed  Google Scholar 

  45. Parsad S, Ratain MJ. Drug-drug interactions with oral antineoplastic agents. JAMA Oncol. 2017;3:736–8. https://doi.org/10.1001/jamaoncol.2016.3323.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy

    Nicola Maurea & Antonietta Caronna

  2. Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Elie N. Mouhayar

Authors
  1. Nicola Maurea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonietta Caronna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elie N. Mouhayar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicola Maurea .

Editor information

Editors and Affiliations

  1. Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy

    Antonio Russo

  2. University of Palermo, School of Medicine, Palermo, Italy

    Giuseppina Novo

  3. Department of Cardiology, University of Liège, Liege, Belgium

    Patrizio Lancellotti

  4. Temple University College of Science and Technology, Philadelphia, PA, USA

    Antonio Giordano

  5. Cardiology Department, University of Lisbon, Lisbon, Portugal

    Fausto J. Pinto

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Maurea, N., Caronna, A., Mouhayar, E.N. (2019). Venous Thromboembolism. In: Russo, A., Novo, G., Lancellotti, P., Giordano, A., Pinto, F. (eds) Cardiovascular Complications in Cancer Therapy. Current Clinical Pathology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-93402-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-93402-0_15

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-93401-3

  • Online ISBN: 978-3-319-93402-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation